Raffaella Cioffi

Dr. Raffaella Cioffi

Department of Gynaecological Oncology, San Raffaele Scientific Institute, 20132 Milan, Italy
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Giorgia MangiliGiorgia Mangili
Giorgia Mangili
GSGiulia Sabetta Sabetta
Giulia Sabetta Sabetta
Raffaella CioffiRaffaella Cioffi
Raffaella Cioffi
EREmanuela Rabaiotti
Emanuela Rabaiotti
GCGiorgio Candotti
Giorgio Candotti
Alice BergaminiAlice Bergamini
Alice Bergamini
Background: Gestational trophoblastic disease includes a rare group of benign and malignant tumors derived from abnormal trophoblastic proliferation. Malignant forms are called gestational trophoblastic neoplasia (GTN) and include invasive mole, choriocarcinoma, placental site trophoblastic tumor and epithelioid trophoblastic tumor. Standard treatment of GTN is chemotherapy. The regimen of choice mainly depends on the FIGO prognostic score. Low-risk and high-risk GTN is treated with single-agent or multiagent chemotherapy, respectively. In the case of chemoresistance, immunotherapy may represent a new therapeutic strategy. Methods: Literature obtained from searches on PubMed concerning GTN and immunotherapy was reviewed. Results: Programmed cell death 1 (PD-1) and its ligands (PD-L1/2) are expressed in GTN. Published data on PD-1/PD-L1 inhibitors alone in GTN were available for 51 patients. Pembrolizumab is an anti-PD-1 inhibitor used in chemoresistant forms of GTN. In the TROPHIMMUN trial, Avelumab, a monoclonal antibody inhibiting PD-L1, showed promising results only in patients with GTN resistant to monochemotherapy. Conversely, in patients with resistance to multiagent chemotherapy, treatment with Avelumab was discontinued due to severe toxicity and disease progression. The association of Camrelizumab and Apatinib could represent a different treatment for forms of GTN refractory to polychemotherapy or for relapses. Conclusions: Anti-PD-1 or anti-PD-L1 might represent an important new treatment strategy for the management of chemoresistant/refractory GTN.

29 August 2019 in Journal of Ultrasound in Medicine
Verified
Journal Article
Closed access
PDF file
Paolo Ivo CavorettoPaolo Ivo Cavoretto
Paolo Ivo Cavoretto
Raffaella CioffiRaffaella Cioffi
Raffaella Cioffi
Giorgia MangiliGiorgia Mangili
Giorgia Mangili
MPMicaela Petrone
Micaela Petrone
Alice BergaminiAlice Bergamini
Alice Bergamini
MSMichael J Seckl
Michael J Seckl

18 April 2022 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
Alice BergaminiAlice Bergamini
Alice Bergamini
FLFais Maria Luisa
Fais Maria Luisa
MDMiriam Dellino
Miriam Dellino
SESilvestri Erica
Silvestri Erica
VLVera Loizzi
Vera Loizzi
GMGiorgia Mangili
Giorgia Mangili
Sex cord stromal tumors are rare neoplasms, frequently diagnosed in young women often as early-stage disease. In patients who desire to preserve fertility, when possible, unilateral salpingo-oophorectomy with peritoneal surgical staging is a safe alternative to radical treatment. In this review, we analyze the available literature on the obstetrical outcomes after fertility-sparing surgery in a total of 255 patients with sex cord stromal tumors. We found that the spontaneous conception rate in granulosa cells tumor is encouraging (88.5%). In particular, juvenile granulosa cell tumors are associated with a more successful pregnancy rate than adult granulosa cells tumors (11/26 (42.3%) in juvenile granulosa cells tumors compared with 28.5% in adult granulosa cell tumors, respectively.) On the other hand, the results of obstetrical outcomes in Sertoli-Leydig cells tumors are less promising (7/36 (19.4%)). Unfortunately, no evidence on this topic is available for sex cord tumor with annular tubules due to the low incidence. Regarding the oncological outcomes of 900 cases of sex cord stromal tumors treated conservatively, data are reassuring with comparable outcomes between patients treated with conservative and radical surgery. Given the limited available data on this rare tumor, further studies are needed to evaluate the safety of conservative approaches and to define the obstetrical outcomes in this patient population.

1 July 2021 in Best Practice & Research Clinical Obstetrics & Gynaecology
Verified
Journal Article
Closed access
VMValentina Di Mattei
Valentina Di Mattei
MMMartina Mazzetti
Martina Mazzetti
GPGaia Perego
Gaia Perego
SRSara Rottoli
Sara Rottoli
GMGiorgia Mangili
Giorgia Mangili
MCMassimo Candiani
Massimo Candiani

4 October 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
ETElena Tassi
Elena Tassi
Alice BergaminiAlice Bergamini
Alice Bergamini
JWJessica Wignall
Jessica Wignall
MSMiriam Sant'angelo
Miriam Sant'angelo
EBEmanuela Brunetto
Emanuela Brunetto
CBChiara Bonini
Chiara Bonini
Introduction: Despite predicted efficacy, immunotherapy in epithelial ovarian cancer (EOC) has limited clinical benefit and the prognosis of patients remains poor. There is thus a strong need for better identifying local immune dynamics and immune-suppressive pathways limiting T-cell mediated anti-tumor immunity.Methods: In this observational study we analyzed by immunohistochemistry, gene expression profiling and flow cytometry the antigenic landscape and immune composition of 48 EOC specimens, with a focus on tumor-infiltrating lymphocytes (TILs).Results: Activated T cells showing features of partial exhaustion with a CD137+CD39+PD-1+TIM-3+CD45RA-CD62L-CD95+ surface profile were exclusively present in EOC specimens but not in corresponding peripheral blood or ascitic fluid, indicating that the tumor microenvironment might sustain this peculiar phenotype. Interestingly, while neoplastic cells expressed several tumor-associated antigens possibly able to stimulate tumor-specific TILs, macrophages provided both co-stimulatory and inhibitory signals and were more abundant in TILs-enriched specimens harboring the CD137+CD39+PD-1+TIM-3+CD45RA-CD62L-CD95+ signature.Conclusion: These data demonstrate that EOC is enriched in CD137+CD39+PD-1+TIM-3+CD45RA-CD62L-CD95+ T lymphocytes, a phenotype possibly modulated by antigen recognition on neoplastic cells and by a combination of inhibitory and co-stimulatory signals largely provided by infiltrating myeloid cells. Furthermore, we have identified immunosuppressive pathways potentially hampering local immunity which might be targeted by immunotherapeutic approaches.

1 December 2018 in Gynecologic Oncology
Verified
Journal Article
Closed access
Giorgia MangiliGiorgia Mangili
Giorgia Mangili
Raffaella CioffiRaffaella Cioffi
Raffaella Cioffi
SDSaverio Danese
Saverio Danese
LFLuigi Frigerio
Luigi Frigerio
GFGabriella Ferrandina
Gabriella Ferrandina
MCMassimo Candiani
Massimo Candiani